
As urged by the AHA, the Drug Enforcement Administration and Substance Abuse and Mental Health Services Administration released a temporary rule extending telehealth prescribing flexibilities for buprenorphine and other controlled substances through Nov. 11, 2024, while they develop final regulations “consistent with public health, safety, and effective controls against diversion.”